For this purpose, DCA was added to primary B chronic lymphocytic leukemia (B-CLL) cells and to primary normal peripheral blood mononuclear cells (PBMC), either alone or in association with Nutlin-3, a small molecule inhibitor of the MDM2/p53 interaction. Here, MDM2 is linked to B-cell chronic lymphocytic leukemia.